Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

European Medicines Agency issues positive opinion, recommends full approval of Pharmacyclics Inc's Imbruvica for treatment of two blood cancers


Friday, 25 Jul 2014 08:52am EDT 

Pharmacyclics Inc:Announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the granting of full marketing approval for Imbruvica (ibrutinib) in the European Union.IMBRUVICA is being jointly developed and commercialized in the United States by Pharmacyclics and Janssen Biotech, Inc.Janssen will market Imbruvica in EMEA (Europe, Middle East, Africa), as well as the rest of the world, outside of the United States.